Previous 10 | Next 10 |
Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021 Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease on track for end of 1Q 2021 Moving towards first patient dosing in thre...
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and c...
Today, we take our first in-depth look at small biotech concern called Wave Life Sciences. Ironically, given its name, the shares go for just over $10 a piece. The company has multiple shots on goal and a partnership with Takeda to develop candidates in the CNS space. A full analy...
CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Exec...
Three clinical trials to begin in 2021 with compounds containing Wave’s novel PN backbone chemistry modifications Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease expected by end of 1Q 2021 Potential best-in-class ADAR editing...
CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Hu...
The following slide deck was published by Wave Life Sciences Ltd. in conjunction with their 2020 Q3 earnings call. For further details see: Wave Life Sciences Ltd. 2020 Q3 - Results - Earnings Call Presentation
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Exec...
Image source: The Motley Fool. WAVE Life Sciences Pte. Ltd. (NASDAQ: WVE) Q3 2020 Earnings Call Nov 9, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: WAVE Life Sciences Pte. Ltd. (WVE) Q3 2020 Earnings Call Transcr...
Wave Life Sciences Ltd. (WVE) Q3 2020 Earnings Conference Call November 9, 2020 8:30 a.m. ET Company Participants Graham Morrell - IR Paul Bolno - President and CEO Mike Panzara - Chief Medical Officer, Head of Therapeutics Discovery and Development Dave Gaiero - Interim CFO Chandra Vargeese ...
News, Short Squeeze, Breakout and More Instantly...
Wave Life Sciences Ltd. Company Name:
WVE Stock Symbol:
NASDAQ Market:
Wave Life Sciences Ltd. Website:
2024-07-17 15:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort ...
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for obesity designed to induce fat burning and preserve muscle mass with once or twice-annual sub...